Annual EBITDA
-$677.70 M
-$199.82 M-41.82%
December 31, 2024
Summary
- As of March 2, 2025, RVMD annual EBITDA is -$677.70 million, with the most recent change of -$199.82 million (-41.82%) on December 31, 2024.
- During the last 3 years, RVMD annual EBITDA has fallen by -$497.95 million (-277.03%).
- RVMD annual EBITDA is now -2171.42% below its all-time high of -$29.84 million, reached on December 31, 2017.
Performance
RVMD EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$212.92 M
-$40.09 M-23.19%
December 31, 2024
Summary
- As of March 2, 2025, RVMD quarterly EBITDA is -$212.92 million, with the most recent change of -$40.09 million (-23.19%) on December 31, 2024.
- Over the past year, RVMD quarterly EBITDA has dropped by -$59.08 million (-38.40%).
- RVMD quarterly EBITDA is now -2194.43% below its all-time high of -$9.28 million, reached on June 30, 2019.
Performance
RVMD Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$677.70 M
-$35.80 M-5.58%
December 31, 2024
Summary
- As of March 2, 2025, RVMD TTM EBITDA is -$677.70 million, with the most recent change of -$35.80 million (-5.58%) on December 31, 2024.
- Over the past year, RVMD TTM EBITDA has dropped by -$87.53 million (-14.83%).
- RVMD TTM EBITDA is now -6284.36% below its all-time high of -$10.62 million, reached on December 31, 2018.
Performance
RVMD TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RVMD EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -41.8% | -38.4% | -14.8% |
| 3 y3 years | -277.0% | -320.7% | -277.0% |
| 5 y5 years | -1294.8% | -562.7% | -565.0% |
RVMD EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -277.0% | at low | -320.7% | at low | -277.0% | at low |
| 5 y | 5-year | -1294.8% | at low | -1077.6% | at low | -1294.8% | at low |
| alltime | all time | -2171.4% | at low | -2194.4% | at low | -6284.4% | at low |
Revolution Medicines EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$677.70 M(+41.8%) | -$212.92 M(+23.2%) | -$677.70 M(+5.6%) |
| Sep 2024 | - | -$172.84 M(+12.3%) | -$641.90 M(+8.8%) |
| Jun 2024 | - | -$153.85 M(+11.4%) | -$590.17 M(+8.6%) |
| Mar 2024 | - | -$138.10 M(-22.0%) | -$543.35 M(+13.7%) |
| Dec 2023 | -$477.88 M(+92.2%) | -$177.13 M(+46.3%) | -$477.88 M(+32.8%) |
| Sep 2023 | - | -$121.10 M(+13.2%) | -$359.86 M(+15.0%) |
| Jun 2023 | - | -$107.02 M(+47.4%) | -$312.86 M(+17.8%) |
| Mar 2023 | - | -$72.62 M(+22.9%) | -$265.59 M(+6.8%) |
| Dec 2022 | -$248.62 M(+38.3%) | -$59.11 M(-20.2%) | -$248.62 M(+3.5%) |
| Sep 2022 | - | -$74.10 M(+24.0%) | -$240.13 M(+10.5%) |
| Jun 2022 | - | -$59.76 M(+7.4%) | -$217.22 M(+8.7%) |
| Mar 2022 | - | -$55.66 M(+10.0%) | -$199.92 M(+11.2%) |
| Dec 2021 | -$179.75 M | -$50.61 M(-1.1%) | -$179.75 M(+11.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$51.19 M(+20.6%) | -$161.26 M(+18.9%) |
| Jun 2021 | - | -$42.46 M(+19.6%) | -$135.65 M(+14.2%) |
| Mar 2021 | - | -$35.49 M(+10.5%) | -$118.77 M(+16.5%) |
| Dec 2020 | -$101.91 M(+109.7%) | -$32.13 M(+25.6%) | -$101.91 M(+16.0%) |
| Sep 2020 | - | -$25.57 M(-0.0%) | -$87.87 M(+18.4%) |
| Jun 2020 | - | -$25.58 M(+37.3%) | -$74.21 M(+28.2%) |
| Mar 2020 | - | -$18.63 M(+3.0%) | -$57.91 M(+19.2%) |
| Dec 2019 | -$48.59 M(+21.7%) | -$18.08 M(+51.7%) | -$48.59 M(+18.2%) |
| Sep 2019 | - | -$11.92 M(+28.4%) | -$41.12 M(+40.8%) |
| Jun 2019 | - | -$9.28 M(-0.3%) | -$29.20 M(+46.6%) |
| Mar 2019 | - | -$9.31 M(-12.3%) | -$19.92 M(+87.7%) |
| Dec 2018 | -$39.91 M(+33.8%) | -$10.62 M | -$10.62 M |
| Dec 2017 | -$29.84 M | - | - |
FAQ
- What is Revolution Medicines annual EBITDA?
- What is the all time high annual EBITDA for Revolution Medicines?
- What is Revolution Medicines annual EBITDA year-on-year change?
- What is Revolution Medicines quarterly EBITDA?
- What is the all time high quarterly EBITDA for Revolution Medicines?
- What is Revolution Medicines quarterly EBITDA year-on-year change?
- What is Revolution Medicines TTM EBITDA?
- What is the all time high TTM EBITDA for Revolution Medicines?
- What is Revolution Medicines TTM EBITDA year-on-year change?
What is Revolution Medicines annual EBITDA?
The current annual EBITDA of RVMD is -$677.70 M
What is the all time high annual EBITDA for Revolution Medicines?
Revolution Medicines all-time high annual EBITDA is -$29.84 M
What is Revolution Medicines annual EBITDA year-on-year change?
Over the past year, RVMD annual EBITDA has changed by -$199.82 M (-41.82%)
What is Revolution Medicines quarterly EBITDA?
The current quarterly EBITDA of RVMD is -$212.92 M
What is the all time high quarterly EBITDA for Revolution Medicines?
Revolution Medicines all-time high quarterly EBITDA is -$9.28 M
What is Revolution Medicines quarterly EBITDA year-on-year change?
Over the past year, RVMD quarterly EBITDA has changed by -$59.08 M (-38.40%)
What is Revolution Medicines TTM EBITDA?
The current TTM EBITDA of RVMD is -$677.70 M
What is the all time high TTM EBITDA for Revolution Medicines?
Revolution Medicines all-time high TTM EBITDA is -$10.62 M
What is Revolution Medicines TTM EBITDA year-on-year change?
Over the past year, RVMD TTM EBITDA has changed by -$87.53 M (-14.83%)